Depletion of serotonin in the nervous system of Aplysia reduces the behavioral enhancement of gill withdrawal as well as the heterosynaptic facilitation produced by tail shock.
Noxious stimuli, such as electrical shocks to the animal's tail, enhance Aplysia's gill- and siphon-withdrawal reflex. Previous experimental work has indicated that this behavioral enhancement, known as dishabituation (if the reflex has been habituated) or sensitization (if it has not been habituated), might be mediated, at least in part, by the endogenous monoaminergic transmitter serotonin (5-HT). To assess 5-HT's role in dishabituation and sensitization of Aplysia withdrawal reflex, we treated Aplysia with the serotonergic neurotoxin 5,7-dihydroxytryptamine (5,7-DHT). We found that 5,7-DHT treatment significantly reduced the dishabituation of the withdrawal reflex produced by tail shock. Treatment with the neurotoxin also blocked the heterosynaptic facilitation of monosynaptic connections between siphon sensory neurons and their follower cells, which contributes to the behavioral enhancement. Analysis by high-performance liquid chromatography indicated that 5,7-DHT treatment significantly reduced 5-HT levels in the Aplysia CNS. Moreover, the neurotoxic effects of 5,7-DHT appeared to be relatively specific for serotonergic pathways. Thus, 5,7-DHT treatment did not disrupt the ability of nonserotonergic facilitatory interneurons, the L29 cells, to facilitate the connections of siphon sensory neurons. Also, 5,7-DHT reduced 5-HT-dependent, but not dopamine-dependent, histofluorescence in Aplysia central ganglia. Finally, 5,7-DHT does not reduce the levels of the facilitatory peptides SCPA and SCPB within the Aplysia CNS. Our results, together with those of Mackey et al. (1989), indicate that 5-HT plays a major role in mediating dishabituation and sensitization of Aplysia's withdrawal reflex.
Glanzman
D L
DL
Howard Hughes Medical Institute, New York, New York 10032.
Mackey
S L
SL
Hawkins
R D
RD
Dyke
A M
AM
Lloyd
P E
PE
Kandel
E R
ER
D015116:5,7-Dihydroxytryptamine / Q000494:pharmacology; D000005:Abdomen / Q000294:innervation; D000818:Animals; D001048:Aplysia / Q000502:physiology*; D001522:Behavior, Animal / Q000502:physiology*; D002490:Central Nervous System / Q000378:metabolism; D004597:Electroshock; D005724:Ganglia / Q000378:metabolism / Q000502:physiology; D005880:Gills / Q000502:physiology*; D006185:Habituation, Psychophysiologic / Q000187:drug effects; D007395:Interneurons / Q000502:physiology; D009420:Nervous System / Q000378:metabolism*; D009434:Neural Pathways / Q000187:drug effects; D009475:Neurons, Afferent / Q000502:physiology; D009479:Neuropeptides / Q000378:metabolism; D012018:Reflex / Q000502:physiology; D012701:Serotonin / Q000378:metabolism*; D013569:Synapses / Q000502:physiology; D013623:Tail
D009479:Neuropeptides; D015116:5,7-Dihydroxytryptamine; D012701:Serotonin